Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

Human Immunodeficiency Virus Clinical Trial

Official title:

Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02479698
• Other study ID #: 2014-0279
• Secondary ID: NCI-2015-0126420
• Status: Recruiting
• Phase: Phase 2
• Start date: July 23, 2015
• Est. completion date: July 31, 2024

Study information

• Verified date: June 2024
• Source: M.D. Anderson Cancer Center
• Contact: Amanda L. Olson, MD
• Phone: 713-792-8750
• Email: ALOlson[@]mdanderson.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.

Description:

PRIMARY OBJECTIVE:

I. To assess the efficacy, feasibility and safety of administering most closely human leukocyte antigen (HLA)-matched BK specific cytotoxic T lymphocyte (CTL) lines (BK-CTLs) generated by ex vivo expansion to mediate antiviral activity in patients with any type of malignancies, and/or human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDs), and/or history of solid organ transplant with BK and JC infections.

SECONDARY OBJECTIVE:

I. To assess the persistence of the administered BK-CTLs generated by ex vivo expansion in patients with any type of malignancies, and/or HIV/AIDs, and/or history of solid organ transplant with BK and JC infections.

OUTLINE:

Patients receive allogeneic BK-specific cytotoxic T-lymphocytes intravenously (IV) over 30 minutes. Patients achieving partial response, stable disease, or progressive disease are eligible for 7 additional infusions of CTL occurring at least 2 weeks after the previous CTL infusion if they meet the eligibility criteria for subsequent therapy.

After completion of study treatment, patients are followed up periodically for 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: July 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with any type of malignancies; and/or HIV/AIDs; and/or history of solid organ transplant; and/or Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) criteria

• Patients with microscopic hematuria OR biopsy proven BK nephritis and urine or blood polymerase chain reaction (PCR) positive for BK virus and/or JC viral encephalitis

• Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg/kg/day of prednisone

• Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion

• Once patients have completed 6-week safety and efficacy assessments after completion of the last anti-BK CTL infusion, patients will be eligible for enrollment on other supportive care protocols

• Written informed consent from patient and/or signed assent from patient, parent or guardian

• Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization; women of child bearing potential must be willing to use an effective contraceptive measure while on study

Exclusion Criteria:

• Patients receiving prednisone > 0.5 mg/kg/day at time of enrollment, or have received anti-thymocyte globulin (ATG) within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment

• Patients with other uncontrolled infections (except HIV/AIDS); for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infection

• Patients with active acute graft-versus-host disease (GVHD) grades II-IV

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• BK Virus Infection
• Carcinoma, Merkel Cell
• Communicable Diseases
• Encephalitis
• Encephalitis, Viral
• HIV Infections
• Human Immunodeficiency Virus
• Immunologic Deficiency Syndromes
• Infections
• JC Virus Infection
• Malignant Neoplasm
• Merkel Cell Carcinoma
• Merkel Cell Polyomavirus Infection
• Polyomavirus Infections
• Viral Encephalitis
• Virus Diseases

Intervention

Biological:
• Allogeneic BK-specific Cytotoxic T-lymphocytes
Given IV

Other:
• Laboratory Biomarker Analysis
Correlative studies

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response, defined as response (R) = (best response [R1] or second best response [R2])	The method of Thall et al will be used to monitor the probabilities of response.	Up to 56 days
Primary	Incidence of acute graft-versus-host disease (GVHD)	The method of Thall et al will be used to monitor the probabilities of grade 3 or 4 GVHD.	Within 28 days of the last dose of cytotoxic T lymphocytes (CTLs)
Primary	Incidence of adverse events	Will be continuously monitored.	Up to day 100
Secondary	Overall survival	Each outcome will be evaluated by tabulation and by fitting a Bayesian statistical regression model for binary outcomes as a function of covar. Unadjusted event time distributions will be estimated using the Kaplan-Meier method.	Up to 12 months
Secondary	Glomerular filtration rate	Each outcome will be evaluated by tabulation and by fitting a Bayesian statistical regression model for binary outcomes as a function of covar. Unadjusted event time distributions will be estimated using the Kaplan-Meier method.	Up to 12 months

External Links

•   University of Texas MD Anderson Cancer Center Website